Lippo Biomedicine Launches "Precision Medicine" to Complete the Development of Consistent and Personalized Medicine
According to the WHO Global Cancer Report 2014, the world ***** 14 million new cancer cases and 8.2 million deaths in 2012, for example. According to the Global Cancer Report 2014 released by WHO, in 2012, for example, there were 14 million new cancer cases and 8.2 million deaths in the world***.
Auto Sync with Cloud
No manual interaction required to synchronize with cloud services.
The Global Cancer Report 2014 study found that cancer cases and deaths increased alarmingly worldwide in 2012, with nearly half of the new cancer cases occurring in Asia, most of them in China. China accounted for 3.07 million new cancer cases (21.9%) and about 2.2 million deaths (26.8%). China leads the world in new cases and deaths of four malignant tumors: liver, esophagus, stomach, and lung.
Precision medicine is an important development for the world in the next decadeWith advances in genomic medicine, the relative importance of genetic variation to disease, especially cancer, is becoming increasingly clear. In terms of cancer treatment, the corresponding relationship between cancer target drugs and gene variant sites affects the success or failure of target drug therapy. President Obama mentioned the Precision Medicine Initiative in his State of the Union address in January 2015, and the details were released on the official White House website in February.
The goal of the U.S. program is to accelerate the use of genetic information to understand disease, in the hope of providing better treatment guidelines and diagnostics to healthcare practitioners. The most critical part of this development is the breakthrough of Next Generation Sequence (NGS) technology. Unlike the current mainstream technology, Real-Time PCR, NGS can provide faster, synchronized sequencing of multiple points, and utilize large databases to quickly complete data matching, providing medical and research personnel with more complete and comprehensive gene sequence information.
Figure/LiPo Biomedical is different from other biotech companies in that it replaces product development with platform development to reduce cost and risk, and completes a consistent linkage from the service side to the product side.
Focusing on Personalized Healthcare from Precision Medicine
Lippo's development strategy is different from other biotech companies in that it replaces product development with platform development to reduce costs and risks, and completes a consistent linkage from the service side to the product side. This not only provides a clear operational direction and main axis, but also effectively avoids the operational risks and company losses that may be caused by single product development and single field development. From detection to treatment, and then to prevention of recurrence, this is the only way to complete a truly personalized medicine development strategy.
Development of Precision Medical TestingLiPo Biomedical prioritizes the development of precision medicine, utilizing the services and technologies of precision medicine to gradually conduct research and product development. Since 2012, Lippo has been cooperating with Taipei Veterans General Hospital (TVGH) to carry out precision medical testing programs, and established the Cancer Genome Medical Laboratory (CGML) to expand substantive technology and develop innovative products, and apply them to medical services. Currently, we are mainly responsible for the molecular testing service for cancer detection in Taipei Veterans General Hospital, and formally issue the test reports.
-Testing Services Lippo utilizes the Ion Torrent equipment developed by Thermo Fisher (formerly Life Tech.) and cooperates with Taipei Veteran's General Hospital to establish the "Cancer Genome Medical Laboratory" in the Taipei Veteran's General Hospital's Medical Science and Technology Building, which not only achieved the world's first NGS technology certification in 2013 but also the world's first NGS technology certification in the world. In 2013, the Laboratory not only obtained the world's first American Academy of Pathology (CAP) certification for sequencing of companion cancer diagnostics utilizing NGS technology, but also obtained the world's first original service provider certification issued by Life Tech (now Thermo Fisher) in the United States in 2013. This award is a world-class recognition of Lippo's use of NGS technology for cancer target drug gene sequencing, and provides hospitals with high-quality test data due to the stability of the technology. Lippo Biomedical is also the first private laboratory in Taiwan to undertake clinical molecular testing for a major hospital (Taipei Veterans General Hospital) utilizing NGS technology. The cancer target drug companion diagnostic service has also passed the Ministry of Health and Welfare's review and is officially listed as a self-funded testing program for the public.
-Collaborative Research Unlike other testing service companies, Lippo Biomedical's development focuses on the application of cancer diagnostics and therapeutics. In addition to pre-treatment screening for targeted cancer drugs, Lippo Biomedical insists that the results of the tests must be used to provide specific feedback to the patient's medication information. Currently, in addition to utilizing the original test reagents from Thermo Fisher (formerly Life Tech.) for testing services, we are also developing a variety of test reagents through research collaboration with the Taipei Veterans General Administration (TVGA). In addition to the original testing reagents from Life Tech, we have also developed a variety of testing reagents through our research collaboration with Taipei Veterans General Hospital. These include target drug testing reagents for colorectal and lung cancers, predictive tests for radiotherapy resistance and target drug effects for ovarian, pancreatic, and bile duct cancers, as well as the development of a comprehensive companion diagnostic reagent panel for all target drugs, which provides not only a high degree of coverage and representativeness of the test sites, but also accurate results and a significant reduction in cost. The cost can also be significantly reduced.
Lippo has developed a variety of test reagents for different cancers, and has completed clinical testing of the standardized products for each of the above tests at the end of 2015, and expects to obtain approval for the medical order service for a variety of new tests for colorectal cancer and other new tests in the second half of 2016. As the newly developed test reagents are accurate and inexpensive, it is expected that after the clinical validation, the medical testing service will be launched in many representative hospitals in the second half of 2016, expanding the service scope and number of people, realizing the operational growth of the service items and increasing the market share.
- Product Development Lippo Biomedical has developed a variety of companion diagnostic tests for cancer target drugs using the Ion Torrent device developed by Thermo Fisher (formerly Life Tech.) as the research and development platform, and has developed a wide range of accurate and inexpensive loci for cancer target drug companion diagnostic tests. The test scope has been extended from the existing approved target drug corresponding to the gene loci, to the clinical research phase I to phase III of the target drug, so it can be expected that in the next three to five years, the market may appear on the target drug of the gene loci of concern, have been covered by Lippo BioScience's development of the test reagents.
Collaboration with medical research institutes to guide and assist in the development of clinical testing productsPhoto/LiPo Biomedical not only collaborates with Taipei Veterans General Hospital for molecular testing of tumors, but also works with Taiwan's major hospitals and research institutes for the development of disease testing and typing, kinship identification technology, and genetic testing technology.
In addition to collaborating with the Taipei Veterans General Hospital on molecular tumor testing, Lippo Biomedical has also been working with major hospitals and research institutes in Taiwan on the development of technologies including, but not limited to, typing of rare diseases (e.g., neuromuscular degenerative diseases commonly known as tachyphylaxis), rapid and most accurate kinship identification technology, and predictive testing for the efficacy of cancer treatments, such as ovarian cancer, as well as flow-through blood cancer cell genetic testing. Technology development. The main purpose of the collection of Taiwan's academic and research community deep foundation, guidance and assistance in the development of clinical testing products, on the one hand, in addition to driving Taiwan's biotechnology industry and the positive cycle of cooperation between the academic community, but also hope to establish a model for Taiwan's industry-academia cooperation, in addition to the Lippo Biomedical substance to achieve technological achievements, but also at the same time to promote Taiwan's biotechnology industry to grow, and for the future of Taiwan's industry to contribute to the development of the heart of the force.
Topics: Personalized medicine, Precision medicine, Lippo